Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer

BACKGROUND: The investigational oral DNA vaccine VXM01 targets the vascular endothelial growth factor receptor 2 (VEGFR-2) and uses Salmonella typhi Ty21a as a vector. The immune reaction elicited by VXM01 is expected to disrupt the tumor neovasculature and, consequently, inhibit tumor growth. VXM01...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Niethammer, Andreas G, Lubenau, Heinz, Mikus, Gerd, Knebel, Philipp, Hohmann, Nicolas, Leowardi, Christine, Beckhove, Philipp, Akhisaroglu, Mustafa, Ge, Yingzi, Springer, Marco, Grenacher, Lars, Buchler, Markus W, Koch, Moritz, Weitz, Jürgen, Haefeli, Walter E, Schmitz-Winnenthal, Friedrich H
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2012
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3493262/
https://ncbi.nlm.nih.gov/pubmed/22906006
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-12-361
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados